These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26984863)
1. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Schmidt M; Lamberts M; Olsen AM; Fosbøll E; Niessner A; Tamargo J; Rosano G; Agewall S; Kaski JC; Kjeldsen K; Lewis BS; Torp-Pedersen C Eur Heart J; 2016 Apr; 37(13):1015-23. PubMed ID: 26984863 [No Abstract] [Full Text] [Related]
2. What price pain relief? Hochman JS; Shah NR Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335 [No Abstract] [Full Text] [Related]
3. More pain for painkillers. Sifferlin A Time; 2013 Jun; 181(24):14. PubMed ID: 24044255 [No Abstract] [Full Text] [Related]
5. Discontinuation of Vioxx. Kim PS; Reicin AS Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669 [No Abstract] [Full Text] [Related]
6. Risk assessment, drug approval, and liability. Somberg JC Am J Ther; 2006; 13(3):181-2. PubMed ID: 16772756 [No Abstract] [Full Text] [Related]
7. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. Konstantinopoulos PA; Lehmann DF J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464 [TBL] [Abstract][Full Text] [Related]
8. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Strand V Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036 [TBL] [Abstract][Full Text] [Related]
9. Vioxx: an unequal partnership between safety and efficacy. Lancet; 2004 Oct 9-15; 364(9442):1287-8. PubMed ID: 15474114 [No Abstract] [Full Text] [Related]
10. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Messerli FH; Sichrovsky T Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380 [No Abstract] [Full Text] [Related]
12. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Schmidt M; Lamberts M; Olsen AM; Fosbøll EL; Niessner A; Tamargo J; Rosano G; Agewall S; Kaski JC; Kjeldsen K; Lewis BS; Torp-Pedersen C Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):108-18. PubMed ID: 27533522 [No Abstract] [Full Text] [Related]
14. Vioxx, the implosion of Merck, and aftershocks at the FDA. Horton R Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041 [No Abstract] [Full Text] [Related]
15. Discontinuation of Vioxx. Garattini S; Bertelé V Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671 [No Abstract] [Full Text] [Related]
16. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204 [No Abstract] [Full Text] [Related]
17. Ibuprofen and cardiovascular safety: where do we stand? Purcell H J R Soc Med; 2007; 100 Suppl 48():7-10. PubMed ID: 18335847 [No Abstract] [Full Text] [Related]
18. Life after Vioxx: the clinical implications. Fortun PJ; Hawkey CJ Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854 [No Abstract] [Full Text] [Related]
19. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. Hohlfeld T; Saxena A; Schrör K Thromb Haemost; 2013 May; 109(5):825-33. PubMed ID: 23238666 [TBL] [Abstract][Full Text] [Related]